1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. North America Molecular Diagnostics for Infectious Disease Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. North America Molecular Diagnostics for Infectious Disease Market – Key Market Dynamics
5.4 Impact of Drivers and Restraints
6. North America Molecular Diagnostics for Infectious Disease Market Regional Analysis
6.1 North America Molecular Diagnostics for Infectious Disease Market Overview
6.2 North America Molecular Diagnostics for Infectious Disease Market Revenue 2020-2030 (US$ Million)
6.3 North America Molecular Diagnostics for Infectious Disease Market Forecast Analysis
7. North America Molecular Diagnostics for Infectious Disease Market Analysis – by Type
7.1 Point-of-Care Testing and Laboratory Testing
- 7.1.1 Overview
- 7.1.2 Point-of-Care Testing and Laboratory Testing: North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2031 (US$ Million)
8. North America Molecular Diagnostics for Infectious Disease Market Analysis – by End User
8.1 Human Testing and Vet Testing
- 8.1.1 Overview
- 8.1.2 Human Testing and Vet Testing: North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Molecular Diagnostics for Infectious Disease Market Analysis – by Application
9.1 Detection of Single Pathogen
- 9.1.1 Overview
- 9.1.2 Human Testing and Vet Testing: North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
9.2 Detection of Two or More Pathogens
- 9.2.1 Overview
- 9.2.2 Human Testing and Vet Testing: North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
9.3 Evaluation of Emerging Novel Infections
- 9.3.1 Overview
- 9.3.2 Human Testing and Vet Testing: North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Surveillance and Early Detection of Biothreat Agents and Diseases-Related Biomarker
- 9.4.1 Overview
- 9.4.2 Human Testing and Vet Testing: North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Antimicrobial Resistance Profiling
- 9.5.1 Overview
- 9.5.2 Human Testing and Vet Testing: North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Patient stratification
- 9.6.1 Overview
- 9.6.2 Human Testing and Vet Testing: North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
9.7 Drug Regimen Selection
- 9.7.1 Overview
- 9.7.2 Human Testing and Vet Testing: North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
9.8 Toxicity Avoidance
- 9.8.1 Overview
- 9.8.2 Human Testing and Vet Testing: North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
9.9 Therapeutic Monitoring
- 9.9.1 Overview
- 9.9.2 Human Testing and Vet Testing: North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
9.10 Detection of Predisposition to Disease
- 9.10.1 Overview
- 9.10.2 Human Testing and Vet Testing: North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Molecular Diagnostics for Infectious Disease Market – North America Analysis
10.1 North America
- 10.1.1 North America Molecular Diagnostics for Infectious Disease Market Breakdown, by Key
Country, 2023 and 2030 (%)
- 10.1.1.1 North America Molecular Diagnostics for Infectious Disease Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 US:
North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.1.1 US: North America Molecular Diagnostics for Infectious Disease Market Breakdown, by Type
- 10.1.1.1.2 US: North America Molecular Diagnostics for Infectious Disease Market Breakdown, by End User
- 10.1.1.1.3 US: North America Molecular Diagnostics for Infectious Disease Market Breakdown, by Application
- 10.1.1.2 Canada:
North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.2.1 Canada: North America Molecular Diagnostics for Infectious Disease Market Breakdown, by Type
- 10.1.1.2.2 Canada: North America Molecular Diagnostics for Infectious Disease Market Breakdown, by End User
- 10.1.1.2.3 Canada: North America Molecular Diagnostics for Infectious Disease Market Breakdown, by Application
- 10.1.1.3 Mexico :
North America Molecular Diagnostics for Infectious Disease Market – Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.3.1 Mexico : North America Molecular Diagnostics for Infectious Disease Market Breakdown, by Type
- 10.1.1.3.2 Mexico : North America Molecular Diagnostics for Infectious Disease Market Breakdown, by End User
- 10.1.1.3.3 Mexico : North America Molecular Diagnostics for Infectious Disease Market Breakdown, by Application
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. North America Molecular Diagnostics for Infectious Disease Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Abbott Laboratories
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 bioMerieux SA
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Bruker Corp
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Danaher Corp
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 DiaSorin SpA
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 F. Hoffmann-La Roche Ltd
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Hologic Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Siemens Healthineers AG
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Thermo Fisher Scientific Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
14. Appendix
14.1 About Business Market Insights
Get Free Sample For North America Molecular Diagnostics for Infectious Disease Market
